← Back to Search

Ophthalmic Solution

VVN539 Ophthalmic Solution 0.02% for Open-Angle Glaucoma

Phase 2
Waitlist Available
Research Sponsored by VivaVision Biotech, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8am, 10am, and 4pm at day 7; day 14 and day 21
Awards & highlights

Study Summary

This trial is testing a new eye drop for people with glaucoma or ocular hypertension. It will compare three different dosing regimens for 7-9 days each.

Eligible Conditions
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8am, 10am, and 4pm at day 7; day 14 and day 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8am, 10am, and 4pm at day 7; day 14 and day 21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Intraocular Pressure
Secondary outcome measures
Mean Change in Intraocular Pressure From Baseline

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: VVN539 Ophthalmic Solution 0.02%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.02%
Group II: VVN539 Ophthalmic Solution 0.04%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.04%
Group III: VVN539 Ophthalmic Solution VehiclePlacebo Group1 Intervention
VVN539 Ophthalmic Solution Vehicle

Find a Location

Who is running the clinical trial?

VivaVision Biotech, IncLead Sponsor
3 Previous Clinical Trials
959 Total Patients Enrolled
Xiao-Yan Li, M.D.Study DirectorVivaVision

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has VVN539 Ophthalmic Solution 0.02% received FDA approval?

"VVN539 Ophthalmic Solution 0.02% received a score of 2 because, while there is safety data from Phase 1 and 2 trials, there is currently no evidence that the solution is effective."

Answered by AI

What is the projected sample size of this research project?

"That is accurate. The most recent information available on clinicaltrials.gov indicates that this trial, which was first advertised on July 12th 2022, is still looking for 60 participants at 1 site."

Answered by AI

Are volunteers still being accepted for this research project?

"Yes, this trial is still recruiting patients according to the information provided on clinicaltrials.gov. This specific study was first posted on July 12th, 2020 and edited more recently on July 19th of the same year."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
What site did they apply to?
Lexitas
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Lexitas: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
2022. "A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05451329.
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top